These techniques are still very much in use. In the Western world, however, there is a tendency to consider these old-fashioned techniques as somewhat hippie-like and indeed very diverged from that of modern medicine studies and research. Fieldwork and product development within the medicine and pharmaceutical industry are mostly done in laboratories and involve highly skilled scientists, budgets and business plans. And though this is not necessarily a bad thing, there could perhaps be some valuable insights and possibilities out there in the nature?

An Australian weed field.

Australian pharmaceutical company Peplin (bought by Denmark-based Leo Pharma in December 2009) are currently working on the development of a new gel to treat Actinic Keratoses (AK), which is the most common pre-cancerous skin condition and caused by excessive sunbathing and use of solariums. And even if most pharmaceutical and medicine companies are constantly working on product development to ensure proper medicine for patients and steady revenue for the company, the story of Peplin’s work with the gel is extraordinary.

For years, Australian locals have used the white sap from a certain weed to cure warts, fight skin cancer and other face lesions. This plant, the Euphorbia Peplus or just Petty Spurge, is actually a common known weed, ruining gardens all over the world – including Denmark and Australia. It came to Peplin’s attention that the plant was worth a study. And the result: it turns out that the sap from the Petty Spurge is indeed very, very powerful and not just the result of a local wonder tale. Besides the gel to treat Actinic Keratoses, Peplin are now conducting heavy research into other products based on the Euphorbia Peplus.

PEP005 is the working title of the gel, which Peplin will launch in 2012 – to a market with a high level of potential: The direct costs for AK in the United States was $1.2 billion in 2004. 58 million people in the United States are living with AK, 11% to 25% of adults in the Northern hemisphere populations and 40% to 60% of adults in Australia have at least one AK lesion.

And the essence of this story? Besides the fact that Peplin’s gel will safe lives, it points towards the potential benefits of moving away from the office or the laboratory. When working with product development, design, manufacturing – in whatever business you are in – we need to realise that we cannot invent everything in the controlled, sterilized environment of our offices or laboratories. We need to get out into the nature, researching wonder tales, talk to people, listen to stories, local traditions and knowledge – in the very same way historic explorers embarked on adventurous scientific and exploratory expeditions.

(Sources: Peplin, Leo Pharma, Wikipedia and Medical News Today)